PMID- 27492657
OWN - NLM
STAT- MEDLINE
DCOM- 20170609
LR  - 20181202
IS  - 1876-4738 (Electronic)
IS  - 0914-5087 (Linking)
VI  - 69
IP  - 5
DP  - 2017 May
TI  - Effects of long-term iloprost treatment on right ventricular function in patients 
      with Eisenmenger syndrome.
PG  - 741-746
LID - S0914-5087(16)30148-4 [pii]
LID - 10.1016/j.jjcc.2016.07.002 [doi]
AB  - BACKGROUND: Right ventricular (RV) function is an important prognostic factor of 
      pulmonary arterial hypertension (PAH), but there is insufficient data regarding 
      RV function after long-term inhaled iloprost treatment. We evaluated the effect 
      of long-term iloprost treatment on RV function in patients with Eisenmenger 
      syndrome (ES). METHODS: Eleven consecutive patients with ES associated with 
      congenital heart disease underwent echocardiographic measurements at baseline and 
      48 weeks after iloprost therapy. In addition, we recorded World Health 
      Organization (WHO) functional class, 6-minute walk distance (6MWD), systemic 
      arterial oxygen saturation (SaO(2)), and laboratory values such as hemoglobin, 
      serum creatinine, and N-terminal pro-B natriuretic peptide. RESULTS: After 48 
      weeks of iloprost therapy, mean pulmonary arterial pressure (mPAP), pulmonary 
      arterial systolic pressure (PASP), and pulmonary vascular resistance (PVR) were 
      significantly decreased [mPAP, 42.5 (38.5-61.0) to 36.5 (29.1-40.0)mmHg; PASP, 
      92.6+/-19.9 to 74.5+/-23.8mmHg; PVR, 23.4 (19.8-26.0) to 23.4 (19.8-26.0)Wood unit 
      respectively, all p<0.05]. There was also significant improvement in RV 
      myocardial performance index [0.68 (0.61-0.80) to 0.52 (0.51-0.62), p=0.003] and 
      RV longitudinal strain (-15.7+/-1.6 to -18.1+/-1.5%, p<0.001). In clinical 
      assessment, WHO functional class (p=0.006), 6MWD (310.6+/-44.7 to 399.7+/-80.8m, 
      p<0.001), and SaO(2) (90.9+/-6.0% to 92.5+/-6.0%, p=0.022) were significantly 
      improved. CONCLUSION: The improvement in echocardiographic parameters of the RV 
      function after 48 weeks of iloprost therapy may provide insight on the efficacy 
      of long-term iloprost treatment for RV functional improvement, which is a 
      prognostic factor in patients with ES.
CI  - Copyright (c) 2016 Japanese College of Cardiology. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Chon, Min Ku
AU  - Chon MK
AD  - Department of Cardiology, Pusan National University Yangsan Hospital, Yangsan, 
      South Korea.
FAU - Cho, Kyoung Im
AU  - Cho KI
AD  - Department of Internal Medicine, Kosin University School of Medicine, Busan, 
      South Korea. Electronic address: kyoungim74@gmail.com.
FAU - Cha, Kwang Soo
AU  - Cha KS
AD  - Department of Cardiology and Medical Research Institute, Pusan National 
      University Hospital, Busan, South Korea.
FAU - Seo, Jeong Sook
AU  - Seo JS
AD  - Department of Internal Medicine, Busan Paik Hospital, University of Inje College 
      of Medicine, Busan, South Korea.
FAU - Kim, Dong Soo
AU  - Kim DS
AD  - Department of Internal Medicine, Busan Paik Hospital, University of Inje College 
      of Medicine, Busan, South Korea.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
DEP - 20160801
PL  - Netherlands
TA  - J Cardiol
JT  - Journal of cardiology
JID - 8804703
RN  - 0 (Vasodilator Agents)
RN  - JED5K35YGL (Iloprost)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Administration, Inhalation
MH  - Adult
MH  - Echocardiography
MH  - Eisenmenger Complex/*drug therapy
MH  - Exercise Test
MH  - Female
MH  - Humans
MH  - Hypertension, Pulmonary/drug therapy
MH  - Iloprost/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Oxygen/blood
MH  - Prospective Studies
MH  - Vascular Resistance/drug effects
MH  - Vasodilator Agents/*therapeutic use
MH  - Ventricular Dysfunction, Right/*drug therapy
OTO - NOTNLM
OT  - Eisenmenger syndrome
OT  - Iloprost
OT  - Pulmonary arterial hypertension
OT  - Right ventricular function
EDAT- 2016/08/06 06:00
MHDA- 2017/06/10 06:00
CRDT- 2016/08/06 06:00
PHST- 2016/03/30 00:00 [received]
PHST- 2016/06/29 00:00 [revised]
PHST- 2016/07/08 00:00 [accepted]
PHST- 2016/08/06 06:00 [pubmed]
PHST- 2017/06/10 06:00 [medline]
PHST- 2016/08/06 06:00 [entrez]
AID - S0914-5087(16)30148-4 [pii]
AID - 10.1016/j.jjcc.2016.07.002 [doi]
PST - ppublish
SO  - J Cardiol. 2017 May;69(5):741-746. doi: 10.1016/j.jjcc.2016.07.002. Epub 2016 Aug 
      1.